à lire
à lire absolument
Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: An overview:Structure, regulation, and clinical implications. Neurobiol Dis 2004; 16:1-13.
Abraham MH. The factors that influence permeation across the blood-brain barrier. Eur J Med Chem 2004;39:235-40.
Fricker G, Miller DS. Modulation of drug transporters at the blood-brain barrier. Pharmacology 2004;70: 169-76.
* Golden PL, Pollack GM. Blood-brain barrier efflux transport. J Pharm Sci 2003;92:1739-53.
Shinkel AH, Smit JJ, VanTellingen O, Beijnen JH, Wagenaar E, Van Deemter L, . Disruption of the mouse MDR1a P-Glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77:491-502.
Begley DJ. ABC transporters and the blood-brain barrier. Curr Pharm Des 2004; 10:1295-312.
* Taylor EM. The impact of efflux transporters in the brain on the development of drugs for CNS disorders. Clin Pharmacokinet 2002;41:81-92.
Mealey KL, Bentjen SA, Gay JM, Cantor GH. Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics 2001; 11:727-33.
* Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein):Recentadvances and clinical relevance. Clin Pharmacol Ther 2004; 75:13-33.
Roberts RL, Joyce PR, Mulder RT, Begg EJ, Kennedy MA. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J 2002;2:191-6.
Furuno T, Landi MT, Ceroni M, . Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson’s disease. Pharmacogenetics 2002;12:529-34.
Siddiqui A, Kerb R, Weale ME, . Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003; 348:1442-8.
Pauli-Magnus C, Feiner J, Brett C, Lin E, Kroetz DL. No effect of MDR 1 C3435T variant on loperamide disposition and central nervous system effects. Clin Pharmacol Ther 2003;74:487-98.
Pardridge WM. Blood-Brain barrier drug targeting: The future of brain drug development. Mol Interv 2003; 3:90-105.
Shen DD, Artru AA, Adkison KK. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev 2004;56:1825-57.
De Lange EC, Danhof M. Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: Implications of the barriers between blood and brain. Clin Pharmacokinet 2002;41:691-703.